Welcome to our dedicated page for Selectquote SEC filings (Ticker: SLQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking SelectQuote’s commission-driven business means digging through pages of deferred revenue tables, carrier-concentration risks, and marketing spend footnotes. If locating policy renewal assumptions in a 300-page 10-K feels overwhelming, you’re not alone.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that translate every SelectQuote SEC filing—whether a dense 10-K or a rapid-fire 8-K—into clear takeaways. Want the latest SelectQuote quarterly earnings report 10-Q filing distilled to cash-flow impacts? Need SelectQuote insider trading Form 4 transactions within minutes of EDGAR release? We provide real-time updates, side-by-side comparisons, and plain-English explanations so you can focus on decisions, not document hunting.
Here’s what you’ll uncover:
- Revenue timing: See how renewal commissions flow through the income statement—no accounting degree required.
- Marketing efficiency: Instantly compare cost-per-policy metrics across quarters with our SelectQuote earnings report filing analysis.
- Governance clarity: Explore SelectQuote proxy statement executive compensation to understand incentive structures.
- Insider behavior: Monitor SelectQuote Form 4 insider transactions real-time and spot buying or selling before enrollment season peaks.
Whether you’re understanding SelectQuote SEC documents with AI, scanning a SelectQuote annual report 10-K simplified, or parsing a sudden SelectQuote 8-K material events explained, Stock Titan keeps every filing at your fingertips—explained simply and updated the moment the SEC posts.
SelectQuote, Inc. reported strategic growth in its healthcare and pharmacy businesses while managing leverage and shifting its distribution mix. Pharmacy revenue rose materially, increasing by $263.9 million (57%) in fiscal 2025 driven by a 31% increase in SelectRx members. Commission and other services revenue declined $59.1 million (7%), led by lower Senior commissions and a 4% decrease in approved policies. The company processed over 1.05 million assisted disclaimers with voice AI and saved over 4.7 million minutes of agent time through automation. SelectQuote reduced total debt to $385.1 million at June 30, 2025 (from $683.3 million prior year) after securitization and debt repayments, and held $37.1 million of cash and equivalents. The business remains concentrated: carriers owned by UHC, Aetna and Humana accounted for 37%, 15%, and 11% of revenue in 2025. The company emphasizes maximizing lifetime value (LTV) through AI-driven lead scoring, agent routing and post-sale retention efforts.
SelectQuote, Inc. (SLQT) filed an amendment to a prior Form 8-K to furnish a corrected press release reporting its financial results for the fourth quarter ended June 30, 2025. The press release was furnished as Exhibit 99.1 and is posted on the company’s Investor Relations website. The filing clarifies that the press release is being furnished (not "filed") for purposes of the federal securities laws and is incorporated by reference only as specified.
Form 4 shows President Robert Clay Grant’s latest equity activity at SelectQuote (SLQT) on 1–2 Aug 2025. Seven tranches of previously granted RSUs and price-vested units vested (transaction code M), delivering ≈631,089 common shares at $0 exercise cost. A day later, 204,163 shares were withheld at $1.74 to cover taxes (code F). Direct ownership after the transactions rose to 2,891,334 shares.
Grant continues to hold significant indirect stakes—1.24 M shares in a personal trust, 184.2 k shares across three children’s trusts, and 1.09 M shares via Haakon Capital—plus unvested derivative holdings. Table II records new equity compensation awards: 460 k time-based RSUs and 460 k price-vested RSUs granted on 1 Aug 2025 (code A), each convertible 1-for-1 into common stock and subject to multi-year vesting/performance hurdles. Remaining unvested derivative balance totals several hundred-thousand units.
FAQ
What is the current stock price of Selectquote (SLQT)?
What is the market cap of Selectquote (SLQT)?
